Radiation Oncology Mobile Application (γ-App)

Radiation Oncology Mobile Application: Symptoms Reporting System and Quality Assurance Tool

To develop a novel a mobile phone application (available on Android and IOS) for patients receiving radiation treatment for head and neck cancer. Through this application, patients will get access to their treatment calender, through a system connected with Mosiac database, which provides a timely and precise access to their treatments schedule.

In addition, patients will be able to report their treatment related toxicity in real time fashion, these symptoms will be addressed daily instead of the weekly floor clinic checks.

Furthermore, the radiation oncologist will receive an instant notification through the application, if there is error in patient's treatment (missing field, wrong dose, etc..)

Study Overview

• Status: Withdrawn
• Conditions: Head and Neck Cancer; Radiation Toxicity

• Study Type: Observational

Contacts and Locations

Study Locations

• Jordan
  • Amman, Jordan, 11941
    • King Hussein Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients referred to our radiation oncology clinic with head and neck cancer.

Description

Inclusion Criteria:

Adult patients receiving definitive or adjuvant RT to head and neck site Chemotherapy is allowed PS:0-1 Has a smart phone

Exclusion Criteria:

Poor performance early laryngeal cancer Patient with metastatic disease, or palliative intent.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
head and neck radiotherapy patients; (Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Grade of symptoms improved with early intervention.	using CTCAE v.5	only during RT (7WEEKS)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
compliance on the mobile.	number of reports.	Only during RT (7WEEKS)

Collaborators and Investigators

• Sponsor: King Hussein Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2019
• Primary Completion (Actual): October 20, 2021
• Study Completion (Actual): October 20, 2021

Study Registration Dates

• First Submitted: October 12, 2018
• First Submitted That Met QC Criteria: October 12, 2018
• First Posted (Actual): October 16, 2018

Study Record Updates

• Last Update Posted (Actual): May 27, 2022
• Last Update Submitted That Met QC Criteria: May 25, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Site; Head and Neck Neoplasms
• Other Study ID Numbers: 18 KHCC 86

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No